Michael Rape is a distinguished scientist and entrepreneur with extensive experience in the field of molecular therapeutics. Currently serving as Co-Founder at Lyterian Therapeutics and as a member of the Scientific Advisory Board for both Vicinitas Therapeutics and Monte Rosa Therapeutics, Michael Rape is also an iPartner at The Column Group. At the University of California, Berkeley, Michael Rape holds the positions of Head of the Division of Molecular Therapeutics and Professor since November 2006. Additionally, as an Investigator with the Howard Hughes Medical Institute since September 2013 and a co-founder and advisory board member at Nurix, Inc. since 2012, Michael Rape demonstrates a strong commitment to advancing scientific research. Michael Rape earned a PhD in yeast genetics from the Max Planck Institute of Biochemistry in Germany between 1999 and 2002.
This person is not in any teams
This person is not in any offices